[go: up one dir, main page]

KR900016098A - 카페인산의 유도체 및 이를 함유하는 약제학적 조성물 - Google Patents

카페인산의 유도체 및 이를 함유하는 약제학적 조성물 Download PDF

Info

Publication number
KR900016098A
KR900016098A KR1019890005689A KR890005689A KR900016098A KR 900016098 A KR900016098 A KR 900016098A KR 1019890005689 A KR1019890005689 A KR 1019890005689A KR 890005689 A KR890005689 A KR 890005689A KR 900016098 A KR900016098 A KR 900016098A
Authority
KR
South Korea
Prior art keywords
formula
caffeic acid
hydrogen atom
derivatives
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1019890005689A
Other languages
English (en)
Inventor
히데쓰라 죠
마사루 우에다
미에 다마오까
미끼꼬 하마구찌
세이이쓰 무로따
이꾸오 모리따
Original Assignee
사하루 게이 죠오
산또리 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP63106274A external-priority patent/JP2557090B2/ja
Priority claimed from JP5586789A external-priority patent/JP2647185B2/ja
Application filed by 사하루 게이 죠오, 산또리 가부시끼가이샤 filed Critical 사하루 게이 죠오
Publication of KR900016098A publication Critical patent/KR900016098A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/34—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring with cyano groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by unsaturated carbon chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

내용 없음.

Description

카페인산의 유도체 및 이를 함유하는 약제학적 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (4)

  1. 일반식(Ⅰ)의 카페인산 유도체와 약제학적으로 허용되는 그들의 염 :
    [상기식에서, X는 수소원자 또는 히드록시이고: R1은 수소원자, 탄소수 1내지 27의 직쇄 또는 측쇄 알킬 또는 알케닐기, 또는 하기식의 기이다 : -(CH2)n-Z-R2(상기식에서, n은 1내지 10의 정수이고: Z은 산소원자, 비닐렌 잔기 또는 단일 결합이고, R2는 치환 또는 비치환된 페닐 또는 헤테로 시클릭 잔기이다)]
  2. 제1항에 있어서, 일반식(Ⅰ)의 R1이 수소원자 또는 탄소원자 1내지 20의 직쇄 또는 측쇄 알킬 또는 알케닐기인 화합물.
  3. 제1항에 있어서, 일반식(Ⅰ)의 R1이 하기식의 기인 화합물: -(CH2)n-Z-R2(상기식에서. n은 1내지 10의 정수이고; Z은 산소원자, 비닐렌잔기 또는 단일결합이고, 및 R2는 치 환 또는 비치환된 페닐 또는 헤테로시클릭 잔기이다)
  4. 약제학적 유효량의 제1항의 화합물을 함유함을 특징으로 하는 순환계 질환 치료제로서 사용되는 약제학적 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890005689A 1988-04-28 1989-04-28 카페인산의 유도체 및 이를 함유하는 약제학적 조성물 Withdrawn KR900016098A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP63-106274 1988-04-28
JP63106274A JP2557090B2 (ja) 1988-04-28 1988-04-28 カフェー酸誘導体およびそれを含む医薬組成物
JP5586789A JP2647185B2 (ja) 1989-03-08 1989-03-08 カフェー酸誘導体及びそれを含む医薬組成物
JP89-55867 1989-03-08

Publications (1)

Publication Number Publication Date
KR900016098A true KR900016098A (ko) 1990-11-12

Family

ID=26396766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890005689A Withdrawn KR900016098A (ko) 1988-04-28 1989-04-28 카페인산의 유도체 및 이를 함유하는 약제학적 조성물

Country Status (6)

Country Link
US (1) US5063243A (ko)
EP (1) EP0339671B1 (ko)
KR (1) KR900016098A (ko)
AT (1) ATE109770T1 (ko)
AU (1) AU618595B2 (ko)
DE (1) DE68917357T2 (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) * 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
GB2238047B (en) * 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
JPH05331129A (ja) * 1990-08-30 1993-12-14 Suntory Ltd カフェー酸誘導体及びそれを含む医薬組成物
JPH05301838A (ja) * 1991-10-15 1993-11-16 Mitsubishi Kasei Corp スチレン誘導体
US5981569A (en) * 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
AU3905599A (en) * 1998-05-20 1999-12-06 City Of Hope Method of treating or preventing abnormal cardiac cell growth by inhibiting the 12-lipoxygenase pathway
US6602515B2 (en) 2001-07-16 2003-08-05 Em Industries Photo stable organic sunscreen compounds with antioxidant properties and compositions obtained therefrom
US6831191B2 (en) 2001-12-20 2004-12-14 Em Industries Photo stable organic sunscreen compounds with antioxidant properties and compositions obtained therefrom
US6699463B2 (en) 2002-04-10 2004-03-02 Em Industries Photostable cationic organic sunscreen compounds with antioxidant properties and compositions obtained therefrom
WO2004016264A1 (ja) * 2002-08-14 2004-02-26 Nissan Chemical Industries, Ltd. トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
US6936735B2 (en) * 2002-08-27 2005-08-30 Emd Chemicals, Inc. Photostable cationic organic sunscreen compounds and compositions obtained therefrom
EP2563359A1 (en) * 2010-04-30 2013-03-06 Allergan, Inc. Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase
CA2860022A1 (fr) * 2011-12-30 2013-07-04 Universite D'auvergne Clermont I Composes anti-douleur
CN113816875A (zh) * 2021-10-26 2021-12-21 北京瑞固科技发展有限公司 材料单体及其制备方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3892777A (en) * 1968-05-01 1975-07-01 Hoffmann La Roche Substituted benzylethylenedicarbamates
US3855301A (en) * 1971-06-28 1974-12-17 Procter & Gamble Novel dihydrochalcone and process
IL38412A (en) * 1971-12-20 1977-02-28 Plantex Ltd Alpha-cyano-3,4,5-trialkoxycinnamic acid derivatives
YU213587A (en) * 1986-11-28 1989-06-30 Orion Yhtymae Oy Process for obtaining new pharmacologic active cateholic derivatives
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation

Also Published As

Publication number Publication date
EP0339671B1 (en) 1994-08-10
EP0339671A3 (en) 1991-05-15
DE68917357T2 (de) 1995-01-26
AU3381389A (en) 1989-11-02
DE68917357D1 (de) 1994-09-15
EP0339671A2 (en) 1989-11-02
AU618595B2 (en) 1992-01-02
US5063243A (en) 1991-11-05
ATE109770T1 (de) 1994-08-15

Similar Documents

Publication Publication Date Title
KR900016098A (ko) 카페인산의 유도체 및 이를 함유하는 약제학적 조성물
KR890701562A (ko) 면역조절 아자스 피란류
KR900006318A (ko) 피페리디닐 벤즈이미다졸
KR880013888A (ko) 신규 디티오아세탈 화합물, 그의 제조방법 및 이 화합물로 되는 제약 조성물
KR910019612A (ko) 옥살릴아미노산 유도체, 이의 제조방법 및 프롤린 하이드록실라제 억제용 약제로서의 이의 용도
KR890016966A (ko) 신규 항바이러스제
KR890012970A (ko) 테트라히드로 이소퀴놀린 유도체
KR970707108A (ko) 항염증제로 유용한, 복소환부를 갖는 디-t-부틸페놀 화합물(DI-TERT-BUTYLPHENOL COMPOUNDS WITH HETEROCYCLIC MOIETY, USEFUL AS ANTI-INFLAMMATORY AGENTS)
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR860700250A (ko) 신규 아미딘 화합물
ATE73449T1 (de) 2-piperazinyl-2-oxo-aethylensubstituierte flavonoid-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammenstellungen.
KR860008973A (ko) 2-피롤리돈 유도체
KR950703941A (ko) 일산화질소 합성 억제제(nitrogen monoxide synthesis inhibitor)
KR910006309A (ko) 인지질 및 인지질 유도체를 유효 성분으로 하는 항비루스성 약제
KR910004557A (ko) 2,4,6-치환 페놀 유도체
KR880012634A (ko) C_17-20리아제 억제제로서 유용한 17β-(사이클로프로필옥시)안드로스트-5-엔-3β-올 및 관련 화합물
KR900016178A (ko) 2-치환 n,n'-디트리메톡시벤조일 피페라진, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR900012925A (ko) 인돌 유도체
ES8603406A1 (es) Un procedimiento para producir derivados de acilindol
KR890001969A (ko) 황화합물, 이들의 제법 및 이들을 함유하는 제약학적 조성물
KR890008148A (ko) 새로운 세파로스포린 화합물 및 항균제
SE9701912D0 (sv) Pharmaceutical composition and use thereof
KR880013896A (ko) 벤조푸로[3,2-c]퀴놀린 화합물
KR880013562A (ko) 7-티아프로스타글란딘e₁ 또는 그의 유도체를 함유하는 당뇨병치료 조성물
KR910015301A (ko) 수면 무호흡증의 치료방법

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890428

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid